Company Website:
http://www.xenonics.com/
CARLSBAD, Calif. -- (Business Wire)
XENONICS HOLDINGS, INC. (OTCBB:XNNH) today announced financial
results for the third quarter and first nine months of fiscal 2013.
Revenue for the three months ended June 30, 2013 decreased to $373,000,
compared to $403,000 for the third quarter of fiscal 2012. The net loss
for the third quarter of fiscal 2013 was $480,000, or $0.02 per share.
This compares to a net loss for the third quarter of fiscal 2012 of
$630,000, or $0.03 per share.
For the nine months ended June 30, 2013, revenue increased to
$1,492,000, compared to $1,200,000 for the first nine months of fiscal
2012. The net loss for this year's first nine months decreased to
$1,267,000, or $0.05 per share. This compares to a net loss for the
first nine months of fiscal 2012 of $1,857,000, or $0.07 per share.
Selling, general and administrative expenses decreased by 28% to
$380,000 for the third quarter of fiscal 2013 from $527,000 for the
third quarter of fiscal 2012. For the first nine months, SG&A decreased
to $1,264,000, compared to $1,587,000 for the same period of the prior
fiscal year.
At June 30, 2013, Xenonics reported total current assets of $2,030,000,
including cash of $185,000, accounts receivable of $60,000, and
inventories of $1,740,000. Total current liabilities at June 30, 2013 of
$2,510,000 included notes payable of $1,898,000 due in October 2013.
"We expect to ship in the current quarter approximately $900,000 of the
$1.2 million NightHunter purchase order we received from Aardvark
Tactical last May. We are pursuing additional orders for our NightHunter
and SuperVision products," said Chairman Alan Magerman.
Conference Call
Xenonics has scheduled a conference call at 11:00 a.m. EDT this morning
to discuss its results for the third quarter of fiscal 2013. The dial-in
number is (877) 703-6109, passcode #72336076. A simultaneous webcast of
the conference call can be accessed from the Webcast
Center of the Investor
Relations link at www.xenonics.com.
A replay will be available after 1:00 p.m. EDT at this same Internet
address. For a telephone replay, dial (888) 286-8010, passcode
#73595683, after 1:00 p.m. EDT.
About Xenonics
Xenonics Holdings, Inc. develops and produces advanced, lightweight and
compact ultra-high-intensity illumination and low-light vision products
for military, law enforcement, public safety, and commercial and private
sector applications. Xenonics' NightHunter line of illumination products
is used by every branch of the U.S. Armed Forces as well as law
enforcement and security agencies. Its SuperVision high-definition night
vision is designed for commercial and military applications. Employing
patented technologies, Xenonics provides innovative solutions for
customers who must see farther so they can do their jobs better and
safer. Xenonics' products represent the next generation in small, high
intensity, high efficiency illumination and low-light vision systems.
Visit Xenonics on the web at www.xenonics.com.
Forward-Looking Statements
Except for the historical statements, statements in this release may
constitute forward-looking statements within the meaning of section 21E
of the Securities Exchange Act of 1934.When used, the words
"anticipates," "believes," "expects," "intends," "future," and other
similar expressions identify forward-looking statements.These
forward-looking statements reflect management's current views with
respect to future events and financial performance and are subject to
risks and uncertainties, and actual results may differ materially from
the outcomes contained in any forward-looking statement.Factors
that could cause these forward-looking statements to differ from actual
results include delays in development, marketing or sales of new
products, and other risks and uncertainties discussed in the company's
periodic reports on Form 10-K and 10-Q and other filings with the
Securities and Exchange Commission.Xenonics Holdings undertakes
no obligation to update or revise any forward-looking statements.
|
|
|
|
| XENONICS HOLDINGS, INC. |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Nine months ended
|
| | |
June 30,
| | |
June 30,
|
| | |
2013
|
|
|
2012
| | |
2013
|
|
|
2012
|
Rounded in thousands, except per share amounts | | |
(unaudited)
| | |
(unaudited)
|
| | |
| | |
| | |
| | |
|
Revenue
| | |
$
|
373,000
| | | |
$
|
403,000
| | | |
$
|
1,492,000
| | | |
$
|
1,200,000
| |
| | |
| | |
| | |
| | |
|
Cost of goods sold
| | |
|
247,000
|
| | |
|
254,000
|
| | |
|
826,000
|
| | |
|
741,000
|
|
| | |
| | |
| | |
| | |
|
Gross profit
| | | |
126,000
| | | | |
149,000
| | | | |
666,000
| | | | |
459,000
| |
| | |
| | |
| | |
| | |
|
Selling, general and administrative
| | | |
380,000
| | | | |
527,000
| | | | |
1,264,000
| | | | |
1,587,000
| |
Research and development
| | |
|
99,000
|
| | |
|
191,000
|
| | |
|
327,000
|
| | |
|
588,000
|
|
| | |
| | |
| | |
| | |
|
Income (loss) from operations
| | | |
(353,000
|
)
| | | |
(569,000
|
)
| | | |
(925,000
|
)
| | | |
(1,716,000
|
)
|
| | |
| | |
| | |
| | |
|
Other income (expense):
| | |
| | |
| | |
| | |
|
Interest (expense)
| | |
|
(127,000
|
)
| | |
|
(61,000
|
)
| | |
|
(340,000
|
)
| | |
|
(139,000
|
)
|
| | |
| | |
| | |
| | |
|
(Loss) before provision for income taxes
| | | |
(480,000
|
)
| | | |
(630,000
|
)
| | | |
(1,265,000
|
)
| | | |
(1,855,000
|
)
|
Income tax provision
| | |
|
--
|
| | |
|
--
|
| | |
|
2,000
|
| | |
|
2,000
|
|
| | |
| | |
| | |
| | |
|
Net (loss)
| | |
$
|
(480,000
|
)
| | |
$
|
(630,000
|
)
| | |
$
|
(1,267,000
|
)
| | |
$
|
(1,857,000
|
)
|
| | |
| | |
| | |
| | |
|
Net income (loss) per share:
| | |
| | |
| | |
| | |
|
Basic
| | |
$
|
(0.02
|
)
| | |
$
|
(0.03
|
)
| | |
$
|
(0.05
|
)
| | |
$
|
(0.07
|
)
|
Fully-diluted
| | |
$
|
(0.02
|
)
| | |
$
|
(0.03
|
)
| | |
$
|
(0.05
|
)
| | |
$
|
(0.07
|
)
|
| | |
| | |
| | |
| | |
|
Weighted average shares outstanding:
| | |
| | |
| | |
| | |
|
Basic
| | |
|
24,976,000
|
| | |
|
24,976,000
|
| | |
|
24,976,000
|
| | |
|
24,976,000
|
|
Fully diluted
| | |
|
24,976,000
|
| | |
|
24,976,000
|
| | |
|
24,976,000
|
| | |
|
24,976,000
|
|
| | | | | | | | | | | | | | | | | | | |
|
| | | | | | | | | | | | | | | | | | | |
|
|
|
|
|
| XENONICS HOLDINGS, INC. |
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
June 30,
|
|
September 30,
|
| | |
2013
| |
2012
|
| Rounded in thousands, except par value | | |
(unaudited)
| | |
| | | | |
|
| Assets | | | | | |
| | | | |
|
|
Current Assets:
| | | | | |
|
Cash
| | |
$
|
185,000
| | |
$
|
367,000
| |
|
Accounts receivable
| | | |
60,000
| | | |
58,000
| |
|
Inventories
| | | |
1,740,000
| | | |
2,117,000
| |
|
Other current assets
| | |
|
45,000
|
| |
|
82,000
|
|
| | | | |
|
|
Total Current Assets
| | | |
2,030,000
| | | |
2,624,000
| |
| | | | |
|
|
Equipment, furniture and fixtures, net
| | | |
14,000
| | | |
14,000
| |
|
Goodwill
| | | |
375,000
| | | |
375,000
| |
|
Other assets
| | |
|
17,000
|
| |
|
17,000
|
|
| | | | |
|
|
Total Assets
| | |
$
|
2,436,000
|
| |
$
|
3,030,000
|
|
| | | | |
|
| | | | |
|
|
Liabilities and Shareholders' Equity
| | | | | |
| | | | |
|
|
Current Liabilities:
| | | | | |
|
Accounts payable
| | |
$
|
360,000
| | |
$
|
281,000
| |
|
Accrued expenses
| | | |
191,000
| | | |
134,000
| |
|
Accrued payroll and related taxes
| | | |
61,000
| | | |
95,000
| |
|
Notes payable, net of debt discount
| | |
|
1,898,000
|
| |
|
1,000,000
|
|
| | | | |
|
|
Total Current Liabilities
| | | |
2,510,000
| | | |
1,510,000
| |
| | | | |
|
|
Notes payable
| | |
|
--
|
| |
|
525,000
|
|
| | | | |
|
|
Total Liabilities
| | |
|
2,510,000
|
| |
|
2,035,000
|
|
| | | | |
|
Commitments and contingencies
| | | | | |
| | | | |
|
|
Shareholders' Equity:
| | | | | |
|
Preferred shares, $0.001 par value, 5,000,000
| | | | | |
|
shares authorized, 0 shares issued and outstanding
| | | |
--
| | | |
--
| |
|
Common shares, $0.001 par value, 50,000,000
| | | | | |
|
shares authorized; 24,976,000 shares issued and
| | | | | |
|
outstanding at June 30, 2013 and September 30, 2012
| | | |
25,000
| | | |
25,000
| |
|
Additional paid-in capital
| | | |
26,879,000
| | | |
26,681,000
| |
|
Accumulated deficit
| | |
|
(26,978,000
|
)
| |
|
(25,711,000
|
)
|
| | | | |
|
|
Total Shareholders' Equity (Deficit)
| | |
|
(74,000
|
)
| |
|
995,000
|
|
| | | | |
|
|
Total Liabilities and Shareholders' Equity
| | |
$
|
2,436,000
|
| |
$
|
3,030,000
|
|
| | | | | | | | |
|
Contacts:
Investor Contact:
Berkman Associates
(310) 477 - 3118
info@BerkmanAssociates.com
or
Company
Contact:
Xenonics Holdings, Inc.
Alan Magerman, Chairman
(760)
477 - 8900
xenonics@xenonics.com
Source: Xenonics Holdings, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.